BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 20, 2025
Home » Topics » Briefs » Regulatory actions

Regulatory actions
Regulatory actions RSS Feed RSS

Regulatory actions for Nov. 1, 2019

Nov. 1, 2019
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations.
Read More

Regulatory actions for Oct. 31, 2019

Oct. 31, 2019
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations.
Read More

Product regulatory actions for October 30, 2019

Oct. 31, 2019
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations.
Read More

New device joins forces with patient network to combat TRS

Oct. 31, 2019
By David Godkin
TORONTO – Health Canada has granted a medical license to Toronto-based pharmaceuticals company Hls Therapeutics Inc. for a device that simplifies blood monitoring for patients suffering from treatment-resistant schizophrenia (TRS).
Read More

Regulatory actions for Oct. 30, 2019

Oct. 30, 2019
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations.
Read More

Product regulatory actions for October 29, 2019

Oct. 30, 2019
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations.
Read More

Regulatory actions for Oct. 22-28, 2019

Oct. 30, 2019
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific.
Read More

Regulatory actions for Oct. 29, 2019

Oct. 29, 2019
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations.
Read More

Regulatory actions for Oct. 28, 2019

Oct. 28, 2019
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations.
Read More

Product regulatory actions for Oct. 25, 2019

Oct. 28, 2019
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations.
Read More
Previous 1 2 … 315 316 317 318 319 320 321 322 323 324 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing